Centessa Pharmaceuticals plc
CNTA
$16.08
-$0.73-4.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.22% | 11.30% | 4.02% | -16.34% | -16.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.84% | 77.44% | 15.41% | -6.46% | -26.16% |
| Operating Income | 14.72% | -112.01% | -15.41% | 6.46% | 26.16% |
| Income Before Tax | 34.15% | -208.97% | -1.17% | 11.91% | 24.93% |
| Income Tax Expenses | 190.44% | -8.22% | 121.51% | 102.93% | -28.95% |
| Earnings from Continuing Operations | 31.31% | -202.22% | -10.14% | -76.07% | 24.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.31% | -202.22% | -10.14% | -76.07% | 24.98% |
| EBIT | 14.72% | -112.01% | -15.41% | 6.46% | 26.16% |
| EBITDA | 14.76% | -112.37% | -15.45% | 6.47% | 26.60% |
| EPS Basic | 48.41% | -124.11% | 8.45% | -53.04% | 28.70% |
| Normalized Basic EPS | 49.08% | -66.18% | 15.69% | 20.12% | 28.15% |
| EPS Diluted | 48.41% | -124.11% | 8.45% | -53.04% | 28.70% |
| Normalized Diluted EPS | 49.08% | -66.18% | 15.69% | 20.12% | 28.15% |
| Average Basic Shares Outstanding | 33.18% | 34.85% | 20.29% | 15.05% | 5.21% |
| Average Diluted Shares Outstanding | 33.18% | 34.85% | 20.29% | 15.05% | 5.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |